Cargando…
Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register
BACKGROUND AND AIMS: The International Atherosclerosis Society (IAS) has proposed that patients with “severe” FH (SFH) would warrant early and more aggressive cholesterol-lowering treatment such as with PCSK9 inhibitors. SFH is diagnosed if LDL-cholesterol (LDLC) > 10 mmol/L, or LDLC >8.0 mmol...
Autores principales: | Humphries, Steve E., Cooper, Jackie A., Capps, Nigel, Durrington, Paul N., Jones, Ben, McDowell, Ian F.W., Soran, Handrean, Neil, Andrew H.W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403443/ https://www.ncbi.nlm.nih.gov/pubmed/30458964 http://dx.doi.org/10.1016/j.atherosclerosis.2018.11.014 |
Ejemplares similares
-
Sex differences in cardiovascular morbidity associated with familial hypercholesterolaemia: A retrospective cohort study of the UK Simon Broome register linked to national hospital records
por: Iyen, Barbara, et al.
Publicado: (2020) -
Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register
por: Humphries, S.E., et al.
Publicado: (2018) -
Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study
por: Neil, Andrew, et al.
Publicado: (2008) -
The UK Paediatric Familial Hypercholesterolaemia Register: preliminary data
por: Ramaswami, Uma, et al.
Publicado: (2017) -
The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1-year growth data
por: Humphries, Steve E., et al.
Publicado: (2018)